InVivo Therapeutics Appoints Mark Perrin As CEO - Quick Facts

(RTTNews) - InVivo Therapeutics Holdings Corp. (NVIV) announced that it has appointed Mark Perrin as Chief Executive Officer or CEO, effective January 6, 2014. Upon his appointment, Perrin will also become a member of the Board of Directors.

Commenting on his prior experience, the company said Perrin most recently served as President of Dennan Consulting, a biotech consulting firm, from 2005 to 2010, he served as President and Chief Executive Officer of ConjuChem Biotechnologies and from 2002 to 2005, he was Executive Vice President and Chief Commercial Officer for Orphan Medical, until it was acquired by Jazz Pharmaceuticals.

Also, from 1995 to 2001, he was Executive Vice President, Commercial Operations for COR Therapeutics and earlier in his career he was Vice President for Burroughs Wellcome and for Lederle Laboratories, with responsibility for U.S. commercial operations at each company, InVivo noted.